Duloxetine for the management of fibromyalgia syndrome

Journal of Pain Research

Volumn 2, Issue , 2009, Pages 99-108

  Scholz, Beth A ^a   Hammonds, Cara L ^a   Boomershine, Chad S ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

Duloxetine; Fibromyalgia; Safety; SNRI

Indexed keywords

DULOXETINE; PLACEBO;

ALCOHOLISM; BEHAVIOR THERAPY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DECREASED APPETITE; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FATIGUE; FIBROMYALGIA; FOOD; FOOD DRUG INTERACTION; HUMAN; HYPONATREMIA; INSOMNIA; LIVER DISEASE; MAJOR DEPRESSION; MOOD DISORDER; NAUSEA; PAIN; PAIN ASSESSMENT; PATIENT ASSESSMENT; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TREATMENT RESPONSE; VOMITING; WEIGHT GAIN; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 77953389291     PISSN: None     EISSN: 11787090     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Wolfe F, et al. The American College of Rheumatology. Criteria for the classification of fibromyalgia. Arthritis Rheum. 1990;33:160-172.
2. Neumann L, Buskila D. Epidemiology of fibromyalgia. Curr Pain Headache Rep. 2003;7:362-368.
3. Katz RS, et al. Fibromyalgia Diagnosis: a comparison of clinical, survey, and American College of Rheumatology criteria. Arthritis Rheum. 2006;54(1):169-176.
4. Berenson A. Drug approved. Is disease real? http://www.nytimes. com/2008/01/14/health/14pain.html?scp=2&sq=fibromyalgia&st=cse. Accessed June 6, 2009.
5. Powers R. Fibromyalgia: an age-old malady begging for respect. J Gen Intern Med. 1993;8(2):93-105.
6. White KP, Thompson J. Fibromyalgia syndrome in an Amish community: A controlled study to determine disease and symptom prevalence. J Rheum. 2003;30(8):1835-1840.
7. Ablin JN, et al. Mechanisms of disease: genetics of fibromyalgia. Nature Clin Pract Rheum. 2006;2(12):671-678.
8. Dadabhoy D, et al. Biology and therapy of fibromyalgia. Evidence-based biomarkers for fibromyalgia syndrome. Arthritis Res Ther. 2008;10(4):211-228.
9. Annemans L, et al. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum. 2008;58(3):895-902.
10. Carville SF, et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008;67: 536-541.
11. Boomershine CS, Crofford LJ. A symptom-based approach to pharmacologic mangement of fibromyalgia. Nat Rev Rheumatol. 2009;5(4):191-199.
12. Boomershine CS, et al. Five visual analogue scales quantify global disease severity and identify clinically significant symptoms in fibromyalgia syndrome. Arthritis Rheum. 2008;58:s686-s687.
13. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheum. 2005; 32(Suppl 75):6-21.
14. Slotkoff AT, et al. The relationship between fibromyalgia and the multiple chemical sensitivity syndrome. Scand J Rheum. 1997;26: 364-367.
15. Sharma J, et al. Pharmakokinetics and safety of duloxetine, a dualserotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol. 2000;40(2):161-167.
16. Trivedi MH, et al. Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. Int Clin Psychopharmacol. 2008;23(3):161-169.
17. Schatzberg AF. Safety and tolerability of antidepressants: weighing the impact on treatment decisions. J Clin Psychiatry. 2007;68(Suppl 8): 26-34.
18. Stahl SM, et al. SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005;10(9):732-747.
19. Deecher DC, et al. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther. 2006;318(2):657-665.
20. Owens MJ, et al. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry. 2001;50:345-350.
21. Westanmo AD, et al. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health Syst Pharm. 2005;62(23): 2481-2490.
22. Fric M, et al. The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry. 2008;41(4):151-155.
23. Preskorn J. Duloxetine. J Psychiatr Pract. 2004;10(6):375-385.
24. Wells KA, Losin WG. In vitro stability, potency, and dissolution of duloxetine enteric-coated pellets after exposure to applesauce, apple juice, and chocolate pudding. Clin Ther. 2008;30(7):1300-1308.
25. Arnold LM, et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arth Rheum. 2004;50(9):2974-2984.
26. Arnold LM, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain. 2005;119(1-3):5-15.
27. Russell IJ. Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6-month, randomized, double-blind, placebo-controlled, fixed-dose trial. Pain. 2008;136(3):432-444.
28. Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating-characteristics, and uses. Clin Exp Rheum. 2005;23(Suppl 39):S154-S162.
29. Cleeland CS, Ryan KM. Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore. 1994;23(2):129-138.
30. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: US Department of Health, Education, and Welfare publication (ADM). National Institute of Mental Health; 1976. p. 76-338.
31. Beck AT, et al. Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess. 1996;67:588-597.
32. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol. 1988;56:893-897.
33. Ware JE, Snow KK, Kosinski M, et al. SF-36 health survey manual and interpretation guide. Boston (MA): The Health Institute, New England Medical Center; 1993.
34. Sheehan DV, et al. The measurement of disability. Int Clin Psychopharmacol. 1996;11(Suppl 3):89-95.
35. Wolfe F, et al. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia syndrome. J Rheum. 1995;22(1):151-156.
36. Retherford RD, Choe MK. Statistical methods for causal analysis. New York: John Wiley & Sons; 1993.
37. http://pi.lilly.com/us/cymbalta-pi.pdf. Accessed May 1, 2009.
38. Hudson JI, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol. 2005;20(5): 327-41.
39. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
40. Fischer AA. Pressure threshold meter: its use for quantification of tender spots. Arch Phys Med Rehabil. 1986;67(11):836-838.
41. Dadabhoy D, et al. Evidence-based biomarkers for fibromyalgia syndrome. Arth Res. Ther. 2008;10(4):211.
42. McCarberg B, et al. Tender points as predictors of distress and the pharmacologic management of fibromyalgia syndrome. Am J Ther. 2003;10(3):176-192.
43. Smets EM, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res. 1995;39:315-325.
44. Brecht S, et al. Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. Int Clin Psychopharmacol. 2008;23(6):317-324.
45. Kluge M, et al. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsychopharmacol. 2007;17(8):527-531.
46. Fishbain DA, et al. Does pain mediate the pain interference with sleep problem in chronic pain? Findings from studies for management of diabetic peripheral neuropathic pain with duloxetine. J Pain Symptom Manage. 2008;36(6):639-647.
47. Culpepper L. Secondary insomnia in the primary care setting: review of diagnosis, treatment, and management. Curr Med Res Opin. 2006;22(7):1257-1268.
48. Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch Gen Psychiatry. 2003;60(1):39-47.
49. Chalon S, et al. Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl). 2005;177(4):357-365.
50. Wright SK, Schroeter S. Hyponatremia as a complication of selective serotonin reuptake inhibitors. J Am Acad Nurse Pract. 2008;20(1): 47-51.
51. Ray WA, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med. 2009;360(3):225-235.
52. Colucci VJ. Heart failure worsening and exacerbation after venlafaxine and duloxetine therapy. Ann Pharmacother. 2008;42(6):882-887.
53. Drent M, et al. Drug-induced pneumonitis and heart failure simultaneously associated with venlafaxine. Am J Respir Crit Care Med. 2003;167(7):958-961.
54. de Abajo FJ, et al. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Brit Med J. 1999;319(7217):1106-1109.
55. Mort JR, et al. Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006;26(9):1307-1313.
56. Sperber AD, et al. Fibromyalgia in the irritable bowel syndrome: studies of prevalence and clinical implications. Am J Gastroenterol. 1999;94:3543-3546.
57. Kurland JE, et al. Prevalence of irritable bowel syndrome and depression in fibromyalgia. Dig Dis Sci. 2006;51:454-460.
58. Brunton LL, editor. Potencies of antidepressants at human transporters for monoamine neurotransmitters. Goodman & Gillman's The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill; 2006.